Form 8-K · Current report
Gilead Sciences 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0000882095
- Accession no.
- 0000882095-26-000028
Summary
Gilead Sciences reported second-quarter 2026 revenues of $7.8 billion, up 10% year over year, while recording a GAAP diluted loss per share of $(8.45) and non-GAAP diluted loss per share of $(6.75), driven by $11.2 billion in acquired IPR&D expenses from its acquisitions of Arcellx, Tubulis and Ouro Medicines. The company updated its full-year 2026 guidance and said HIV sales grew 12%, led by Biktarvy and Descovy, while Veklury sales fell 81%.
Key points
- Total Q2 2026 revenues rose 10% to $7.8 billion; product sales excluding Veklury rose 10% to $7.6 billion.
- GAAP diluted loss per share was $(8.45) and non-GAAP diluted loss per share was $(6.75), reflecting $11.2 billion in acquired IPR&D expenses primarily from the Arcellx ($7.0 billion), Tubulis ($3.1 billion) and Ouro Medicines ($1.0 billion) acquisitions.
- HIV product sales rose 12% to $5.7 billion; Biktarvy sales rose 7% to $3.8 billion; Descovy sales rose 48% to $967 million; Veklury sales fell 81% to $23 million.
- Gilead's full-year 2026 guidance now includes product sales of $30.1–$30.4 billion and GAAP diluted loss per share of $(3.75)–$(3.40), compared with prior guidance of $(3.25)–$(2.85).
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 4, 2026, Gilead Sciences, Inc., a Delaware corporation (“Gilead”), announced its financial results for the quarter ended June 30, 2026. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.